Cargando…
Alzheimer’s Disease at a Crossroad: Time to Part from Amyloid to More Promising Aspects—Atherosclerosis for a Start
Three decades with the amyloid hypothesis, nearly two with amyloid-PET imaging, and one with testing of anti-amyloid therapy have not yielded benefits to patients with Alzheimer’s disease (AD). It is time to focus on more promising options, e.g., infection, low dose radiation, and atherosclerosis. T...
Autores principales: | Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Alavi, Abass |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200191/ https://www.ncbi.nlm.nih.gov/pubmed/35599491 http://dx.doi.org/10.3233/JAD-220190 |
Ejemplares similares
-
Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022) -
Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022) -
Can Target-to-Background Ratio Measurement Lead to Detection and Accurate Quantification of Atherosclerosis With FDG PET? Likely Not
por: Alavi, Abass, et al.
Publicado: (2022) -
Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023) -
FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)